Get the Stockscreener App
28.69
4.46%
-1.34
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edgewise Therapeutics' SWOT analysis: novel therapies drive stock potential - MSN
Can you now get a good deal on Edgewise Therapeutics Inc’s shares? - US Post News
When (EWTX) Moves Investors should Listen - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpStill a Buy? - MarketBeat
Ratios Uncovered: Breaking Down Edgewise Therapeutics Inc (EWTX)’s Trailing Twelve Months Metrics - The Dwinnex
Check out these key findings about Edgewise Therapeutics Inc (EWTX) - SETE News
Edgewise Therapeutics' SWOT analysis: novel therapies drive stock potential By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 25,000 Shares - MarketBeat
Paradigm Biocapital Advisors LP Increases Stake in Edgewise Ther - GuruFocus.com
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Update - MarketBeat
Moody Aldrich Partners LLC Has $5.02 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics names new COO - MSN
Edgewise Therapeutics reshuffles executive team - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 7.1%Here's What Happened - MarketBeat
Edgewise elevates chief operating officer, hires development exec - BizWest
Edgewise Therapeutics Promotes Behrad Derakhshan, Ph.D., to Chief Operating Officer Role - Defense World
Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? - Yahoo Finance
New COOs for Vividion, Edgewise - BioCentury
Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownWhat's Next? - MarketBeat
Edgewise Therapeutics names new COO By Investing.com - Investing.com Australia
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development - BioSpace
Edgewise Therapeutics (NASDAQ:EWTX) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Edgewise Therapeutics Strengthens Leadership Team, Appoints Merck Veteran as Chief Development Officer - StockTitan
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target By Investing.com - Investing.com Canada
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Increases By 8.9% - Defense World
Edgewise Therapeutics Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
JPMorgan Chase & Co. Boosts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1%Should You Sell? - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
December 19th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
How to Take Advantage of moves in (EWTX) - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Trading 7.4% HigherHere's What Happened - MarketBeat
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 - Business Wire
Edgewise Therapeutics Advances Muscular Dystrophy Drug Sevasemten, Nears Pivotal Trial Milestone - StockTitan
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):